BidaskClub Upgrades Quanterix (NASDAQ:QTRX) to “Sell”

Quanterix (NASDAQ:QTRX) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday, BidAskClub reports.

QTRX has been the subject of a number of other reports. Canaccord Genuity restated a “buy” rating and set a $36.00 price objective on shares of Quanterix in a research note on Wednesday. Zacks Investment Research downgraded shares of Quanterix from a “buy” rating to a “hold” rating in a report on Wednesday, June 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $33.67.

NASDAQ:QTRX traded down $0.87 on Friday, reaching $32.31. 690,626 shares of the stock traded hands, compared to its average volume of 188,982. The company has a market capitalization of $914.73 million, a price-to-earnings ratio of -20.07 and a beta of 1.77. The company has a current ratio of 6.80, a quick ratio of 6.17 and a debt-to-equity ratio of 0.06. Quanterix has a 12 month low of $10.90 and a 12 month high of $35.76. The company’s fifty day simple moving average is $27.76 and its 200 day simple moving average is $24.80.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). The firm had revenue of $15.73 million for the quarter, compared to the consensus estimate of $12.70 million. Quanterix had a negative net margin of 70.51% and a negative return on equity of 36.97%. Equities analysts anticipate that Quanterix will post -1.67 EPS for the current fiscal year.

In related news, SVP David C. Duffy sold 1,667 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $26.52, for a total value of $44,208.84. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Martin D. Madaus sold 1,600 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $27.86, for a total transaction of $44,576.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,116 shares of company stock worth $1,657,246. Insiders own 25.40% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Macquarie Group Ltd. increased its position in Quanterix by 18.8% in the fourth quarter. Macquarie Group Ltd. now owns 1,337,857 shares of the company’s stock worth $31,614,000 after purchasing an additional 211,947 shares during the last quarter. BlackRock Inc. increased its position in Quanterix by 2.5% in the first quarter. BlackRock Inc. now owns 1,233,402 shares of the company’s stock worth $22,659,000 after purchasing an additional 29,680 shares during the last quarter. Frontier Capital Management Co. LLC increased its position in Quanterix by 58.7% in the second quarter. Frontier Capital Management Co. LLC now owns 837,220 shares of the company’s stock worth $22,931,000 after purchasing an additional 309,584 shares during the last quarter. Ashford Capital Management Inc. increased its position in Quanterix by 5.0% in the first quarter. Ashford Capital Management Inc. now owns 652,524 shares of the company’s stock worth $11,987,000 after purchasing an additional 31,010 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC increased its position in Quanterix by 16.3% in the first quarter. Silvercrest Asset Management Group LLC now owns 274,373 shares of the company’s stock worth $5,040,000 after purchasing an additional 38,357 shares during the last quarter. 69.28% of the stock is currently owned by institutional investors.

About Quanterix

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

See Also: What is a stock portfolio tracker?

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.